Multiple cytokine profiling of the therapeutic responses to ribavirin and pegylated interferon-2b using an "induction" approach with natural interferon- in difficult-to-treat chronic hepatitis C

Journal of Interferon and Cytokine Research

Volumn 29, Issue 6, 2009, Pages 353-368

  Kishida, Yutaka ^a   Haruna, Yoshimichi ^b   Naitoh, Masahumi ^c   Katayama, Kazuhiro ^c   Kashiwagi, Toru ^d  

^a OSAKA UNIVERSITY   (Japan)

^b Osaka Prefectural General Medical Center   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CARBON TETRACHLORIDE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 8; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALOPECIA; ARTICLE; BIOMETRY; BLOOD SAMPLING; CEREBROSPINAL FLUID; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; LEUKOPENIA; LIVER BIOPSY; MAINTENANCE THERAPY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; CYTOKINES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-BETA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; SEROLOGIC TESTS; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME; VIRAL LOAD; VIRULENCE;

HEPATITIS C VIRUS;

EID: 66249105012     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0110     Document Type: Article

References (59)

1. Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abriguani S, Mondelli MU, Bamaba V. 2004. Hepatic expansion of a virus-specif c regulatory CD8+ T cell population in chronic hepatitis C virus infection. J Clin Invest 113:963-972.
2. Barnes E, Harcourt G, Brawn D, Lucas M, Philips R, Dusheiko G, Kleneman P. 2002. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36:743-754.
3. Berg T, Von Wagner M, Naser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. 2006. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130:1086-1097.
4. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Lemon SM, Lanford RE. 2004. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78(24):13779-13792.
5. Biron CA, Brossay L. 2001. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 13:458-464.
6. Boni C, Penna A, Ogg GS, Bertoletti A, Peli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Ficcadori F, Ferrali C. 2001. Lamivudine treatment overcome cytotoxic T-cell hyporespon-siveness in chronic hepatitis B; New Perspectives for Immune Therapy. Hepatology 33:963-997.
7. Carotenirto P, vau Riel D, Artesen A, Brujus S, Uytdehang FG, Laman JD, Van Nunen AB, Zonderrau PE, DeMan RA, Osterhaus AD, Pontesilli O. 2005. Antiviral treatment with alpha interferon up-regulates CD 14 on liver macrophages and its soluble form in patients with chronic hepatitis B. Antimicrob Agents Chemother 49(2):590-599.
8. Chan HLY, Ren H, Chow WC, Wee T, on behalf of the Interferon beta 1a Hepatitis C Study Group. 2007. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 46:315-323.
9. Chung RT, Gale Jr M, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. 2008. Mechanism of action of interferon and ribavirin in chronic hepatitis C; Summary of a Workshop. Hepatology 47(1):306-320.
10. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abriguani S, Valiante NM. 2002. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195:35 - 41.
11. Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. 2005. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage virion production. Gastroenterlogy 128:1056-1066.
12. Da Silvia AJ, Brickelmaier M, Majeau GM, Lukashin V, Peyman J, Whity A, Hochman PS. 2002. Comparison of gene expression patterns induced by treatment of human umbilical vein endo-thelial cells with IFN-alpha2b vs IFN-beta 1a understanding the functional relationship between distinct type 1 interferons that act through a common receptor. J Interferon Cytokine Res 22:173-188.
13. Davis GL, Wong JB, Mchuchison JG, Manns M P, Harvey J, Albrecht J. 2003. Early virologic response to treatment with peginter-feron Alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38:645-652.
14. Domarski P, Nadeau OW, Platanias LC, Fish E, Kellum M, Pitha P, and Colamonici OR. 1998. Differential use of the BL subunit of the type 1 interferon (IFN) receptor determines signaling specif city for IFN-alpha 2 and beta. J Biol Chem 273:3144-3147.
15. Foy E, Li K, Sampter Jr L, Loo YM, Johnson CL, Wang C, Mar Fish P, Yoneyama M, Fujita T, Lemon SM, Gale Jr M. 2005. Control of antiviral defenses through hepatitis C virus disruption of ret-inoic acid-inducible gene-1 signaling. Proc Natl Acad Sci USA 102:2986 -2991.
16. Frese M, Schwazele V, Barth K, Kriegger N, Lohmann V, Mihm S, Haller O, Bartenschlager R. 2002. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35:694-703.
17. Fried TMW. 2000. Natural history and disease manifestation of hepatitis C infection. Curr Topic Microbial Immunol 242:43-54.
18. Fried MW, Schiffman ML, Reddy KR, Smith C, Marinos G, Gonzarez Jr FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alpha-2a plus riba-virin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
19. Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang M, Zhang H, Zhou C, Yao J, Jin L, Wang H, Yang Y, Fu Y-X, Wang F-S. 2007. Increased regulated T cell correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132:2328-2339.
20. Gao B, Jeong W-I, Tian Z. 2008. Liver: an organ with predominant innate immunity. Hepatology 47:729-736.
21. Global Surveillance and Control of Hepatitis C. 1999. Report of WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepatitis 6:35-47.
22. Hellier S, Frodsham AJ, Henning, BJ, Klenerman P, Knap S, Ramaley P, Satsangi J, Wright M, Zhang L, Thomas HC, Thursz M, Hill AVS. 2003. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2 with outcome of HCV infection. Hepatology 38:1468-1476.
23. Herzer K, Falk CS, Enche J, Eichhorst ST, Ulsenheimer A, Seliger B, Kammer PH. 2003. Upregulation of major histocompatibility complex class I on liver cells by Hepatitis C virus core protein via p53 and TAP I impairs natural killer cell cytotoxicity. J Virol 77:8299-8309.
24. Hiasa Y, Kuzuhara H, Tokumoto Y, Konishi I, Yamashita N, Matsuura B, Michitaka K, Chung R T, Onji M. 2008. Hepatitis C virus replication is inhibited by 22 beta-methoxyolean-12-ene-3beta, 24 (4beta)-diol (ME3738) through enhancing interferonbeta. Hepatology 48:59-70.
25. Ishak K, Baptista A, Bianchi L, Callea F, Degroote J, Gudat F, Denk H, Desmet V, Korb G, Maasween RN. 1995. Histological grading and staging of chronic hepatitis C. J Hepatol 22:696-699.
26. Kanto T, Hayashi N, Takehara T, Tatsumi T, Kuzushita N, Ito A, Sasak i Y, Kasa hara A, Hori M. 1999. Impaired allosti mu latory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 162:5584-5591.
27. Khakoo SI, Thio CL, Martin M P, Brooks CR, Gao X, Astermborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg MC, Thomas DL, Carrington M. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872-874.
28. Kieffer TL, Sarrazin C, Miller JS, Weller MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. 2007. Telaplevir and pegylated interferon-alpha-2a inhibit wild -type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631-639.
29. Kishida Y, Naitoh M, Katayama K, Kashiwagi T. 2003. Clearance of hepatitis C virus with the optimal Cyclic and Periodic Interferon Treatment regimen consisting of induction treatment with natural interferon-beta followed by maintenance treatment with interferon-alpha in interferon-resistant patients (Abstract). Gastroenterology 124 (3) suppl.:T1224.
30. Kishida Y, Haruna Y, Kashiwagi T, Matsuura N. 2004. Prevention of viral escape in chronic hepatitis C virus infection with ribavirin plus IFN-alpha 2b or pegylated IFN-alpha 2b: Use of an induction approach combining Cyclic and Periodic Interferon Treatment with natural IFN-beta and IFN-alpha (Abstract). Proceedings of the 1st Dominique Dormont International conference (Host Pathogen Interaction in Chronic Infection); December 3-4, Paris, France. p. 35.
31. Lau D-Y, Fish PM, Sinha M, Owen DM, Lemon SM, Gale Jr M. 2008. Interferon regulatory factor 3 activation, hepatic interferon-stim-ulated gene expression, and immune cell inf ltration in hepatitis C patients. Hepatology 47:799-809.
32. Li B, Sun R, Wei H, Gao B, Tian Z. 2006. Interleukin 15 prevents concanavalin A induced liver injury in mice via cell-dependent mechanism. Hepatology 43:1211-1219.
33. Li XD, Sun L, Seth RB and Pineda G. 2005. Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 102:17717-17722.
34. Lichterfeld M, Leifeld L, Nischalke HD, Rochstone JK, Hesse L. Sauerbruch J, Spengler U. 2002. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface lexpression peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J Infect Dis 15, 185 (12):1803-1807.
35. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida M, Yonetama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT-Y, Weiman SA, Lemon SM, Gale Jr M. 2006. Viral and therapeutic control of IFN-beta promoter stimulator and during hepatitis C virus infection. Proc Natl Acad Sci USA 103:6001-6006.
36. Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, Feinstone SM. 2004. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in Chimpanzees. Hepatology 39:1709-1720.
37. Manns MP, Mchutchison JG, Gordon SC, Rustgi VK, Schiffman M, Reindollav R, Goodman Z, Konry K, Liang MM, Albrecht JK, The International Hepatitis Interventional Therapy Group. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomized trial. Lancet 358:958-965.
38. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgen JD for the Euro SPIA study group. 2007. Normalization of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiviral therapy: an observational cohort study. Lancet 370:407-413.
39. Mughes CA, Shafran S D. 2006. Chronic hepatitis C virus management; 2000-2005 update. Am Pharmacother 40:74-82.
40. Narumi S, Tominaga Y, Tamura M, Shimai S, Okumure H, Nishioji K, Itoh Y, Okanoue T. 1997. Expression of IFN-inducible pro-tein-10 in chronic hepatitis. J Immunol 158:5536-5544.
41. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden JJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral eff cacy of interferon-alpha therapy. Science 282:103-107.
42. Pawlotsky JM. 2004. Hepatitis C: it's a long way to new therapy, it's a long way to go. Gastroenterology 127:1629-1631.
43. Platanias LC, Shahab Udclin S, Colamonics OR. 1994. Tyrosine phosphorylation of the alpha and beta Subunit of the Type 1 Interferon Receptor. J Biol Chem 269(27):17761-17764.
44. Polyak SJ, Khabar KS, Rezeig M, Gretch DR. 2001. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 75:6209-6211.
45. Rahman F, Heller T, Sobao Y, Mizukoshi E, NascimbeniI M, Alter H, Herrine S, Hoofnagle J, Liang TJ, Rehermann B. 2004. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 40:87-97.
46. Rico MA, Quinga JA, Subira D, Rico MA, Quiroga JA, Subira D, Castanon S, Esteban JM, Pardo M, Carreno V. 2002. Hepatitis B Virus Specif c T cell Proliferation and Cytokine Secretion in Chronic Hepatitis B e Antibody Positive Patients Treated with Ribavirin and Interferon-alpha. Hepatology 36:743-754.
47. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, Chawla YK, Jain RK, Nanda V, Kumar A, Hissar S, Lavate P, Lahoti P, National Collaborative Group on Hepatitis B, India. 2007. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 102:96-104.
48. Sharma P, Marrero JA, Fontana RJ, Geenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS. 2007. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related early virologic response and dose adherence. Liver Transplant 13(8):1100-1108.
49. Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, Mckinney D, Rogendorf M, Von Weizsacker E, Blume HE, Thimme R. 2005. Intrahepatic C D 8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 42:828-837.
50. Szabo G, Dolganiuc A. 2006. HCV immunopathogenesis: virus-induced strategies against host immunity. Clin Liver Dis 10:753-771.
51. Szabo G, Chang S, Dolganiuc A. 2007. Altered innate immunity in chronic hepatitis C infection; cause or effect? Hepatology 46:1279-1290.
52. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRF family of transcription factors as regulators of host defense. Ann Rev Immunol 19:623-655.
53. Tassopoulos NC, Tsantoulas D, Raptopoulou M, Vassiliadis T, Kanatakis S, Paraskevas E, Vaf adis I, Argerinos A, Tzanthas C, Manoulakopoulos S, Keitikoglou I, Aggelis P, Garitsask K, Giannoulis G, Hatzis G, Thomopoulos K, Akviviadis E, Sypsa V, Hatzakis A. 2003. A randomized trial to assess the eff cacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C; superior eff cacy of high daily dose of interferon alpha in genotype 1. J Viral Hepatitis 10:189-196.
54. Urbani S, Boni C, Missale G, Elia GF, Cavallo C, Massari M, Raimond G, Ferrali C. 2002. Same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 76:12423-12434.
55. Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, Watanabe M. 2001. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN eff cacy in hepatitis C virus genotype 1b infection. J Infect Dis 183: 1195-1203.
56. Wertheimer AM, Bakke A, Rosen HR. 2004. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 40:335-345.
57. Wertheimer AM, Polyak SJ, Leistikow R, Rosen HR. 2007. Engulfment of Apoptotic Cells Expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology 45:1422-1432.
58. Wright H, Alex P, Nguyen T, Bader T, Gurakar A, Sebastian A, Gonzales L, Wallis G, Naylor M, Domorov I, Centola M, Nour B. 2005. Multiple cytokine prof ling of initial therapeutic response in patients with chronic hepatitis C virus infection. Digest Dis Sc i 50(10):1793-1803.
59. Yee LJ, Tang J, Gibson A W, Kimberly R, Van Leeuwen DJ, Kasalow RA. 2001. Interleukin 10 polymorphism as predictors of sustained response in antiviral therapy for the chronic hepatitis C infection. Hepatology 33:708-712.